hydralazine has been researched along with EHS Tumor in 19 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Excerpt | Relevance | Reference |
---|---|---|
"To test this hypothesis, we reduced blood flow in subcutaneously grown Radiation Induced Fibrosarcoma-1 (RIF-1) tumors, either by creating partial ischemia with a bolus injection of hydralazine or by occlusion with surgical sutures." | 3.69 | Reduced blood flow increases the in vivo ammonium ion concentration in the RIF-1 tumor. ( Constantinidis, I; Gamcsik, MP, 1995) |
"The effects of the vasodilator hydralazine (HYD) on microcirculatory function and hyperthermic response were studied in early generation isotransplants of a spontaneous C3Hf/Sed mouse fibrosarcoma (FSall)." | 3.68 | Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors. ( Kalmus, J; Okunieff, P; Vaupel, P, 1990) |
"The effects of the two vasodilating substances, dihydralazine and the adrenergic alpha-receptor blocker phenoxybenzamine, were studied on the distribution and growth of MCG-L-SS metastases from intravenously injected tumour cells." | 3.65 | Alteration of metastases distribution by vaso-dilating drugs. ( Boeryd, B; Hagmar, B; Johnsson, G; Ryd, W, 1975) |
"When nigericin and EIPA were combined with administration of hydralazine, the surviving fraction of cells in both tumors was reduced by a factor of 0." | 1.29 | Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH. ( Hasuda, K; Lee, C; Tannock, IF, 1994) |
"Hydralazine, which may cause tumour hypoxia and lower pHi as well as pHe, caused cytotoxity when given alone by chronic infusion, and enhanced the cytotoxicity due to nigericin." | 1.29 | The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. ( Tannock, IF; Yamagata, M, 1996) |
"Both nigericin and CCCP were observed to penetrate tissue based on their ability to kill tumour cells in spheroids." | 1.28 | Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours. ( Newell, K; Stratford, I; Tannock, I; Wood, P, 1992) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (15.79) | 18.7374 |
1990's | 15 (78.95) | 18.2507 |
2000's | 1 (5.26) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jones, GR | 1 |
Frohn, MJ | 1 |
Beckett, AH | 1 |
Constantinidis, I | 1 |
Gamcsik, MP | 1 |
Hasuda, K | 1 |
Lee, C | 1 |
Tannock, IF | 3 |
Luo, J | 1 |
Bhujwalla, ZM | 1 |
Shungu, DC | 1 |
Chatham, JC | 1 |
Wehrle, JP | 1 |
Glickson, JD | 1 |
Belfi, CA | 2 |
Paul, CR | 1 |
Shan, S | 1 |
Ngo, FQ | 2 |
Yamagata, M | 1 |
Lee, J | 1 |
Siemann, DW | 2 |
Koch, CJ | 1 |
Lord, EM | 1 |
Rao, BS | 1 |
Devi, PU | 1 |
Begg, AC | 1 |
Hofland, I | 1 |
Van Der Pavert, I | 1 |
Van Der Schueren, B | 1 |
Haustermans, K | 1 |
Boeryd, B | 1 |
Hagmar, B | 1 |
Johnsson, G | 1 |
Ryd, W | 1 |
Thomas, C | 1 |
Counsell, C | 1 |
Sansom, J | 1 |
Wood, P | 2 |
Stratford, I | 2 |
Adams, G | 1 |
Newell, K | 1 |
Tannock, I | 1 |
Ting, LL | 1 |
Hassenbusch, SJ | 1 |
Tefft, M | 1 |
Bremner, JC | 2 |
Counsell, CJ | 1 |
Adams, GE | 3 |
Stratford, IJ | 3 |
Wood, PJ | 1 |
Dunn, JF | 1 |
Radda, GK | 1 |
Bowler, J | 1 |
Kalmus, J | 1 |
Okunieff, P | 1 |
Vaupel, P | 1 |
Godden, J | 1 |
Nolan, J | 1 |
Howells, N | 1 |
Timpson, N | 1 |
19 other studies available for hydralazine and EHS Tumor
Article | Year |
---|---|
Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ.
Topics: Animals; Antineoplastic Agents; Cell Survival; Dihydralazine; Drug Resistance; Energy Metabolism; Hu | 1984 |
Reduced blood flow increases the in vivo ammonium ion concentration in the RIF-1 tumor.
Topics: Animals; Fibrosarcoma; Hydralazine; Ligation; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C3 | 1995 |
Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH.
Topics: Amiloride; Animals; Cell Hypoxia; Cell Survival; Combined Modality Therapy; Drug Screening Assays, A | 1994 |
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy.
Topics: Amiloride; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimida | 1994 |
Glucose metabolism in RIF-1 tumors after reduction in blood flow: an in vivo 13C and 31P NMR study.
Topics: Acidosis; Alanine; Animals; Autoradiography; Blood Glucose; Carbon Isotopes; Energy Metabolism; Fema | 1994 |
Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI.
Topics: Animals; Dose-Response Relationship, Drug; Gadolinium DTPA; Hydralazine; Magnetic Resonance Imaging; | 1994 |
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Amiloride; Animals; Antineoplastic Agents; Antipor | 1996 |
Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Topics: Anemia; Animals; Antibodies, Monoclonal; Carbon Dioxide; Cell Hypoxia; Cell Survival; Etanidazole; F | 1996 |
Multimodality treatment using AK-2123, hydralazine, radiation & hyperthermia on a transplantable mouse tumour.
Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Mice; Mice, Inbred B | 1996 |
Use of thymidine analogues to indicate vascular perfusion in tumours.
Topics: Animals; Blood Flow Velocity; Female; Flow Cytometry; Hydralazine; Idoxuridine; Image Processing, Co | 2000 |
Alteration of metastases distribution by vaso-dilating drugs.
Topics: Animals; Dihydralazine; Hydralazine; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred CBA; Neopla | 1975 |
The perfluorocarbon emulsion PFOB: potential indicator of change in blood volume using fluorine-19 NMR spectroscopy.
Topics: Animals; Blood Volume; Carcinoma, Squamous Cell; Contrast Media; Fluorocarbons; Hydralazine; Hydroca | 1992 |
Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours.
Topics: Amiloride; Animals; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Division; Cell Survival; Fibrosa | 1992 |
Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging.
Topics: Animals; Blood Circulation; Hydralazine; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Neoplas | 1992 |
In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.
Topics: Animals; Colonic Neoplasms; Humans; Hydralazine; Magnetic Resonance Spectroscopy; Melanoma, Experime | 1991 |
Bioreductive drugs and the selective induction of tumour hypoxia.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Constriction; Hydralazine; Mice; Mice, Inbred C3H; Mis | 1990 |
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cyclophosphamide; Drug Synerg | 1990 |
Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSall tumors.
Topics: Animals; Blood Pressure; Female; Fibrosarcoma; Heart Rate; Hydralazine; Hyperthermia, Induced; Laser | 1990 |
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Hydralazine; Male; Melphal | 1988 |